BioPharma Dive March 26, 2024
Participants in a Phase 1 study lost up to 5% of their body weight, while treatment was associated with a low rate of side effects.
Dive Brief:
- A dual-acting weight loss pill from Viking Therapeutics helped people with obesity lose up to 5% of their body weight over four weeks in a small trial designed to identify a dose for more advanced studies, the company said Tuesday.
- The news helped Viking rebound from a stock slump that followed Novo Nordisk’s announcement a similar weight loss pill it’s developing drove double-digit weight loss over three months in a larger, more advanced trial.
- One Wall Street analyst noted the Viking drug’s “exceptional tolerability” may separate it from medicines being developed by...
Today's Sponsors
Today's Sponsor